Published in Cancer Weekly, April 27th, 2004
The study enrolled 170 patients at 22 North American sites, with 89 randomized to Dacogen plus supportive care and 81 randomized to supportive care only.
Supportive care included antibiotics, growth factors, and/or transfusions. The data analysis was performed after 92 patients reached the primary endpoint of either progression to acute myelogenous leukemia (AML) or death.
Patients randomized to the Dacogen arm had an increased time to progression to AML or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.